Abstract:Volumetric muscle loss (VML) resulting from extremity trauma presents chronic and persistent functional deficits, restricted joint range of motion, and fibrosis, which ultimately manifest disability. Currently, there is a clinical need for therapies aimed at addressing the debilitating outcomes due to VML injuries. Recent investigations have examined the use of commercially available biological scaffolds as a regenerative medicine approach for VML. However, there is a paucity of large animal data to advance clinical translation. We hypothesized that repair of VML injuries with an acellular biologic scaffold would improve function, specifically neuromuscular strength following injury. To test this hypothesis, female Yorkshire Cross pigs (n=10) were randomized to sham or an ~20% VML injury to the peroneous tertius muscle, and injuries were left non‐repaired, or surgically repaired with an acellular biologic scaffold derived from either porcine small intestinal submucosa (SIS) or urinary bladder matrix (UBM) using standard clinical surgical implantation procedures. Analysis of muscle volume using CT imaging and muscle function via peroneal nerve stimulation was conducted through 12 weeks post‐injury. At this terminal time‐point, full thickness biopsy samples were used for histological analysis and sequencing of RNA extracted from the injured muscle tissue. All studies were conducted in compliance with the Animal Welfare Act, the Implementing Animal Welfare Regulations and in accordance with the principles of the Guide for the Care and Use of Laboratory Animals. Unexpected adverse advents occurred in 80% of the VML injuries repaired with the SIS scaffold. Both the repair with SIS and UBM resulted in a significant fibrotic response and increased volume of the anterior compartment. However, this volume could not be attributed to increased muscle, as histologic analysis of the muscle indicated sub‐physiologic islands of muscle fibers (~50 fibers). To understand the quality of muscle, peak muscle torque was normalized to the CT‐derived volume of the anterior compartment at 10 weeks post‐injury. Collectively in the non‐ and ECM‐repaired limbs there was ~45% deficit compared to sham operated limbs. Additionally, in both the non‐ and ECM‐repaired limbs there was an ~30% deficit in absolute peak isometric torque through 12 weeks post‐injury. Tissue level RNA sequencing analysis of the non‐repaired and surgically repaired samples compared to Sham controls revealed increases in expression of sets of genes associated with inflammatory signaling and fibrogenesis and downregulation of myogenic repair gene sets. Quantitative comparison of the transcriptomes from surgically repaired samples against the non‐repaired samples indicated high degrees of correlation amongst the differentially expressed genes. These results indicate the gene expression programs induced from a VML insult are not appreciably augmented when treated with surgical repair of an acellular biologic scaffold. Collectively, these data indicate that VML results in extensive and continued disruption of the remaining musculature and that ECM repair does not ameliorate the resulting pathobiology.

Human muscle in gene edited pigs for treatment of volumetric muscle loss

Humanized skeletal muscle in MYF5/MYOD/MYF6-null pig embryos

Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy

Toward the correction of muscular dystrophy by gene editing

Regenerative medicine for skeletal muscle loss: a review of current tissue engineering approaches

In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy

Skeletal Muscle Tissue Engineering: Biomaterials-Based Strategies for the Treatment of Volumetric Muscle Loss

Meganucleases Revolutionize the Production of Genetically Engineered Pigs for the Study of Human Diseases

Acellular Biological Scaffold Repair Does Not Overcome the Pathobiology of Volumetric Muscle Loss Injury

Efficient Generation of Myostatin Mutations in Pigs Using the CRISPR/Cas9 System

Optimization of Xenografting Methods for Generating Human Skeletal Muscle in Mice

Tissue Engineered 3D Constructs for Volumetric Muscle Loss

Recent Advances and Future of Gene Therapy for Bone Regeneration

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

CRISPR/Cas9-Mediated Gene Editing in Porcine Models for Medical Research

Vascularized and Innervated Skeletal Muscle Tissue Engineering

Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases

Therapeutic Sources of Skeletal Muscle Regeneration from Volumetric Muscle Loss: A Narrative Review

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

Scaffold tissue engineering strategies for volumetric muscle loss